entertainment -WSS

entertainment

author：entertainment 2025-10-03 00:38:28 - browse：87

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Vertex Pharmaceuticals may move headquarters in Boston

explore

WSS

CDC panel: People 65 and older should get a Covid spring booster shot

Color Health wants to make cancer screenings convenient

Study fuels hope CAR

Elisabeth Bik tackles the widespread issue of research misconduct

Roche subsidiary Foundation Medicine opens new headquarters

Redefining sustainability for the pharmaceutical industry

knowledge

entertainment

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why the world’s most expensive drug might be worth the price

How to save PrEP access — and even expand it

Scientists boost immune system in aging mice by making it youthful

Drug repurposing or repositioning? The language matters

Merck drug for rare lung condition set for approval in U.S.

Apple is now the first public company to be valued at $3 trillion

Elisabeth Bik tackles the widespread issue of research misconduct

Cancer drug shortages should be causing more outrage

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

knowledge

Decaf coffee targeted by food safety group under obscure FDA rule

Study says nonprofit hospitals fall short in charity care spending

Washington mulls new rules to avert another Change Healthcare

5 ways to address the shortage of health care workers

Medicare Advantage isn’t working — for anyone

Patient advocates debate FDA's accelerated approval process

explore

knowledge

hotspot

knowledge